S: therapeutic effects by cilostazol and

bmjopen-2016-011824S: therapeutic effects by cilostazol and bmjopen-2016-011824 title=View Abstract(s)">PubMed 2-Chloro-5,6-dihydro-7H-cyclopenta[b]pyridin-7-one ID:https://www.ncbi.nlm.nih.gov/pubmed/12711626 potentiation by dipyridamole. Platelets. 2004;15:167?2. 129. Nomura S, Shouzu Omoto S, Nishikawa M, Iwasaka T. 5-HT2A receptor antagonist increases circulating adiponectin in patients with type 2 diabetes mellitus. Blood Coagul Fibrinolysis. 2005;16:423?. 130. Baj-Kizyworzeka M, Majka M, Oratico D, Ratajczak J, Vilaire G, Kijowski J, et al. Platelet-derived microparticles stimulate proliferation, survival, adhesion, and chemotaxis of hematopoietic cells. Exp Hematol. 2002;30:450?. 131. Nomura S, Kanazawa S, Inami N, Kamitsuji Y, Uoshima N, Ishida H, et al. Role of platelet-derived chemokines (RANTES and ENA-78) after stem cell transplantation. Transpl Immunol. 2006;15:247?3. 132. Nomura S, Ishii K, Inami N, Uoshima N, Ishida H, Yoshihara T, et al. Role of soluble tumor necrosis factor-related apoptosis-inducing ligand concentration after stem cell transplantation. Transpl Immunol. 2007;18:115?1. 133. Majka M, Kijowski J, Lesko E, Gozdzik J, Zupanska B, Ratajczak MZ. Evidence that platelet-derived microvesicles may transfer platelet-specific immunoreactive antigens to the surface of endothelial cells and CD34+ hematopoietic stem/progenitor cells ?implication for the pathogenesis of immune thrombocytopenias. Folia Histochem Cytobiol. 2007;45:27?2. 134. Deregibus MC, Cantaluppi V, Calogero R, Lo Iacono M, Tetta C, Biancone L, et al. Endothelial progenitor cell-derived microvesicles activate an angiogenic program in endothelial cells by a horizontal transfer of mRNA. Blood. 2007;110:2440?.Nomura and Shimizu Journal of Intensive Care (2015) 3:Page 11 of135. Janowska-Wieczorek A, Wysoczynski M, Kijowski J, Marquez-Curtis L, Machalinski B, Ratajczak J, et al. Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. Int J Cancer. PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/9638577 2005;113:752?0. 136. Ratajczak J, Miekus K, Kucia M, Zhang J, Reca R, Dvorak P, et al. Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery. Leukemia. 2006;20:847?6. 137. Kanazawa S, Nomura S, Kuwana M, Muramatsu M, Yamaguchi K, Fukuhara S. Monocyte-derived microparticles may be a sign of vascular complication in patients with lung cancer. Lung Cancer. 2003;39:145?. 138. Janowska-Wieczorek A, Marquez-Curtis LA, Wysoczynski M, Ratajczak MZ. Enhancing effect of platelet-derived microvesicles on the invasive potential of breast cancer cells. Transfusion. 2006;46:1199?09. 139. Kalinkovich A, Tavor S, Avigdor A, Kahn J, Brill A, Petit I, et al. Functional CXCR4-expressing microparticles and SDF-1 correlate with circulating acute myelogenous leukemia cells. Cancer Res. 2006;66:11013?0. 140. Yu JL, May L, Lhotak V, Shahrzad S, Shirasawa S, Weitz JI, et al. Oncogenic events regulate tissue Methyl 3-fluoro-2-thiophenecarboxylate factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood. 2005;105:1734?1. 141. DelConde I, Bharwani LD, Dietzen DJ, Pendurthi U, Thiagarajan P, Lopez JA. Microvesicle-associated tissue factor and Trousseau's syndrome. J Thromb Haemost. 2007;5:70?. 142. Tesselaar ME, Romijn FP, Van Der Linden IK, Prins FA, Bertina RM, Osanto S. Microparticle-associated tissue factor activity: a link between cancer and thrombosis ? J Thromb Haemost. 2007;5:520?. 143. Tilley RE, Holscher T, Belani R, Nieva J, Mackman N. Tissue factor activity is increased in a combined platelet and microparticle sample from cancer patients. Thromb Res. 2008;122:6.